Twigman,
I think you are a bit harsh on the Lupus trial. Remember this is under FDA protocols. The trial must first prove safety at low doses before it can move to higher doses. It must first prove safety in mild Lupus before moving to more severe conditions. These are the protocols set by the FDA. Their prime concern is patient safety. The first two cohorts did two things. They allowed IVX to move to a cohort at higher doses and allowed them to now seek permission for dosing in patients with more severe disease. The very tight selection criteria for patients in the first two cohorts appear to have excluded any patients with sufficiently advanced symptoms to shown any statistically significant improvement. Frustrating as this may be, it does not in any was indicate negative results. It is simply part of the process imposed by the FDA. Hopefully IVX will now be able to move to slightly more advanced conditions and show some statistically significant improvement.
IVX Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)